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Letter to the Editor 
In the last years, collaborative studies have joined to link the degree of genetic 
heterogeneity of acute myeloid leukemia (AML) to clinical outcome1,2, allowing risk 
stratification before therapy and guiding post-induction treatment of children with AML. So 
far, still half of these patients, whose disease is usually characterized by a grim prognosis, 
lack a known biomarker offering opportunities of targeted treatment. This relevant 
limitation prompted to pursue the search of new prognostic biomarkers to address also 
these forms of still uncharacterized AML. We chose to investigate NUP98 for its attitude to 
rearrange with different gene partners and produce oncogenic fusion transcripts often 
found to be associated with a wide range of hematological disorders, including leukemia3. 
NUP98-rearrangements have been mainly mechanistically associated with oncogenic 
activation of HOX-AB cluster genes, a process largely documented for MLL-rearranged 
AML4–6, in cooperation with other recurrent genetic defects, in particular FLT3-ITD7. The 
frequency and prognostic relevance of NUP98 fusions in a single-center cohort of 
childhood AML has been recently reported8, but neither the frequency nor the role of 
diverse NUP98 partners have been investigated. Here, we report an exhaustive molecular 
screening of twelve NUP98 rearrangements in the Italian pediatric patients with de novo 
AML enrolled in the AIEOP AML 2002/01 trial9. By RT-PCR, we characterized, at 
diagnosis, 494 patients harboring CBF rearrangements (RUNX1-RUNX1T1 and CBFB-
MYH11, N=99), MLL-translocations (N=86), FLT3-ITD (N=54), and rarer 
mutations/translocations (N=83)7,10, while in 172 patients no mutations were detected 
(35%). Among these 172 patients without known mutations and 36 patients with isolated 
FLT3-ITD11 mutation we searched for NUP98 rearrangements with NSD1, HOXC11, 
PHF23, HOXA9, JARID1A, HOXD13, LEDGF, DDX10, HHEX, ADD3, NSD3 and 
LOC348801, finding 16 (9.3%) with 6 different NUP98-fusions (16/172 = 9.3%) and 9 with 
t(5;11)NUP98-NSD1, respectively (9/36=25%, Tab. 1S and 2S). In the 16 patients with 
NUP98 fusions, no CEBPA mutations were found, while 2 patients had K-RAS mutation, 
one of which concomitant with NPM1 mutation. Survival analyses revealed that the 
NUP98-t (N=16) had a significant worse event-free survival (EFS, 25%) compared to the 
rest of AML (49.7%) patients without known mutations (N=156, Neg in Fig. 1A, p<0.01), 
and significantly higher incidence of relapse (Fig.1A, 66.3% vs 33.6% p-value<0.01, 
Tab.1S). Reduced EFS and increased CIR were found also in the 9 NUP98-t patients with 
a concomitant FLT3-ITD mutation similar to isolated t(5;11) (Fig. 1A). Collectively, in the 
whole AIEOP-AML trial cohort, we identified 25 NUP98-t patients (5%) characterized by a 
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severe prognosis (Fig. 1SA-C). We then characterized NUP98-rearranged patients (n=19) 
by using gene expression profiling (GEP) and compared them to 66 cases of AML with 
various genetic abnormalities (see supplementary methods, GSE75461). Supervised 
clustering showed that most of the NUP98-AML cases grouped independently of the rest 
of AML cases (Fig. 1B, Fold Change>|1.5|, p-value<0.01, Fig. 2SA, Tab. 3SAB). In 
particular, the coding transcript clusters revealed 76 differentially expressed mRNAs (p-
value<0.05), where most of the upregulated genes were confirmed to belong to the HOX 
family, in particular the HOX-B cluster (see non coding clustering analysis at Fig. 2SB), 
and the most downregulated were all genes involved in mitosis and nuclear division 
(CPNE8, CPNE3, CCNA1, FAS, DEFA423 being also validated by RQ-PCR Fig. 2SC). By 
gene ontology, we confirmed their involvement in the regulation of mitosis and chromatin 
modification (Fig. 2SD, Tab. 4S), this finding supporting the role of NUP98-fusions in 
increasing genome instability12. We further investigated this finding in ex vivo blasts 
obtained at diagnosis from t(5;11)NUP98-NSD1-rearranged patients and implanted in 
NSG mice (see supplementary methods). We revealed spindle assembly checkpoint 
(SAC) defects in total cell extracts from NUP98-t cells arrested in M-phase after treatment 
with the microtubule-depolymerizing drug nocodazole (Noco), but no defects were found in 
BM cells from healthy donors (HBM) used as control. MAD2 and BUB1 protein levels 
decreased starting from 8 hours post-Noco treatment, while Cyclin B levels increased, 
indicating that NUP98-t cells had an early and uncontrolled entrance in mitosis (Fig. 3SA). 
Then, we blocked DNA replication using aphidicolin (APH) and found an increased number 
of mitotic chromosomal breaks 24 hours post treatment in NUP98-t cells compared to 
HBM cells (Fig. 3SB). This latter result was confirmed by protein analysis, which showed 
PP2A subunit β in the cytoplasm and phosphorylated H2AX (γH2AX) in the nucleus for the 
recruitment of enzymes to repair DNA in NUP98-t cells. This phenomenon was absent in 
HBM cells, where γH2AX was detected in the cytoplasm and PARP was found to be 
cleaved, suggesting that apoptosis occurred probably due to incapability of healthy cells to 
repair DNA and survive at the same APH dose (Fig. 1C). 
We then moved to NUP98 partner gene characterization, finding evidence that 
NUP98-t patients significantly differentially expressed 101 transcript clusters independently 
of what was found in the rest of AML cases (60 coding and 41 non-coding RNAs, Tab. 4S, 
Kruskal-Wallis test, p-value<0.01) (Fig. 2A, Tab. 5S). We focused our attention on HOX-
AB cluster genes expression and found that, having NSD1 as partner gene, conferred the 
lowest HOX-AB expression among the six different NUP98-translocations (Fig. 2A, Fig. 
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4SA, p-value<0.05). Different GEP sustained a different survival depending on partner 
gene, with NSD1 mediating the worst prognosis (NSD1 N=12; PHF23+JARID1A N=7, Fig. 
4SBC, p<0.05). In order to identify peculiarities among the different NUP98-fusions, we 
performed enrichment analysis for several selected molecular signatures (see 
supplementary methods). We found that all were enriched in chromosome instability and 
HOX/MLL signatures, with the exception of that involving PHF23, which showed 
correlation with methylation6 (Fig. 2B, Tab. 6S), and NUP98-JARID1A, confirmed to be 
typically involved in AML with megakaryoblastic features13. This analysis recognized the 
NUP98-NSD1 rearranged patients being significantly enriched of the cAMP signaling, the 
GSK3 inhibitor pathway and CREB targets gene sets, identifying the cAMP response 
element binding protein (CREB) as a likely key player among these overrepresented 
signatures (Fig. 2B, Fisher test *p-value<0.05). Gene set enrichment analysis further 
confirmed that NUP98-t transcriptional profiles were enriched in genes dependent on 
CREB activity, i.e. cAMP and GSK3 signaling (Fig. 5SA). CREB is a proto-oncogene in 
pediatric AML, and its overexpression has been largely demonstrated to induce aberrant 
cell proliferation and cell-cycle regulation of hematopoietic cells14. We investigated in vitro 
if CREB could be involved in the transcriptional control of NUP98 and NUP98-fusions 
strengthened by the presence of CREB consensus regions (the cAMP response elements, 
CREs) at the site of the NUP98 promoter (from 1,300 bases upstream of the NUP98 
transcription start site). By chromatin immunoprecipitation, we confirmed that CREB 
worked as transcription factor at the NUP98 gene promoter in myeloid leukemia cells (Fig. 
5SB). Furthermore, we co-expressed exogenous CREB (pEGFP-flag-CREB) with a 
reporter gene (LUC) under the control of the wild type-NUP98 promoter, revealing that 
CREB mediated LUC over-activation. On the contrary, when we induced mutagenesis at 
CREs, LUC activity significantly decreased. Moreover, by CREB gene silencing, LUC 
activity was found to be reduced, as well as NUP98 protein levels (Fig. 2C, Fig. 5SC), 
confirming the hypothesis of CREB controlling NUP98 gene expression. The same 
experiment of CREB genetic silencing was performed in ex vivo cells from three AML 
patients at diagnosis harboring t(5;11)NUP98-NSD1, revealing a reduced NUP98-NSD1 
chimera at both RNA and protein levels (Fig. 6SAB, p-value<0.01). These results for the 
first time show that inhibiting CREB and its binding to the NUP98 promoter may constitute 
a reliable strategy 15 to destabilize NUP98-chimera expression.  
In summary, we screened twelve NUP98 rearrangements in a large pediatric cohort of 
Italian children with AML and found that six of them identified a new subgroup of recurrent 
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somatic translocations with a total frequency of 5%. NUP98-rearranged patients had an 
incidence of relapse higher than that of the general high-risk AML, resulting into poorer 
EFS. We found that NUP98-leukemia arises as a sequence of biologically distinct 
phenomena where each partner gene plays a unique role and that NUP98-fusions identify 
a novel AML subgroup functionally independent from the rest of AML. To the best of our 
knowledge, this is the first study documenting in primary NUP98-NSD1-rearranged 
leukemia cells an altered spindle assembly checkpoint and an aberrant response to DNA 
damage. These evidences confirmed that NUP98 cells suffer from enhanced genomic 
instability, which may contribute to a more pronounced transcriptional variability and to the 
acquisition of cooperating mutations, which can concur to the severe prognosis. 
Collaborative studies in larger cohorts are warranted to yield additional insights into the 
clinical and biological role played by NUP98 fusion transcripts. Notably, we documented 
that CREB is the transcriptional factor controlling NUP98 expression; thus, its targeting 
could be further investigated as a novel potential strategy for the treatment of this subtype 
of AML. 
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Figure legends  
Figure 1. Characterization of NUP98-t pediatric AML. A) EFS probability and CIR in 9 
and 16 children with NUP98-t with and without FLT3-ITD, respectively, as compared to the 
molecularly negative patients enrolled in the Italian AML cohort (p-value< 0.05). 
Abbreviations: N, number of cases; EFS, event free survival; CIR, cumulative incidence of 
relapse. B) Supervised hierarchical clustering analysis (using 76 differentially expressed 
coding RNAs (p-value<0.01). C) Western blot of lysates after APH treatment. The 
expression of PP2A-B55α in the cytoplasm and γH2Ax in the nucleus of NUP98-NSD1 
primary cells revealed cell integrity and chromosome instability, whereas cytoplasmic 
γH2Ax and the increased PARP cleaved (cl) in the HBM revealed that apoptosis occurred. 
β-ACTIN and PARP1 total (total) represent the loading controls of cytoplasmic and nuclear 
extracts, respectively.  
Figure 2. NUP98 partner genes confer different expression profiles and CREB drives 
their expression. A) Left panel shows supervised hierarchical clustering analysis using 
the 101 probe sets identified by Kruskal-Wallis test among 19 NUP98-t patients (p-
value<0.01). Right panel shows HOXA-B cluster analysis of pediatric NUP98-t patients. B) 
Molecular signature enrichment analysis. A significant molecular signature is indicated by 
a black box (*p-value<0.05 for NUP98-NSD1 cases versus all the others). C) NUP98-wild 
type and mutated promoter sequence was cloned in the LUC-vector-pXP2-NUP98prom 
and pXP2-NUP98prom CRE mut, respectively. Luciferase (LUC) activity was measured in 
HEK293T transient co-transfection of pXP2-NUP98prom with pEGFP-flag-CREB plasmid 
or siR-NEG and SiR-CREB. The vector alone (pXP2) has been used as control. (N=3, 
normalized with Renilla (REN) activity). 
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